Researchers request clinical trials for osteoporosis drug to treat COVID-19

Researchers have requested clinical trials to study the potential of the osteoporosis drug raloxifene as a potential treatment for COVID-19.

Researchers have requested clinical trials to study the potential of the osteoporosis drug raloxifene as a potential treatment for COVID-19. The Exscalate4CoV research consortium, which is funded by the European Union, virtually screened more than 400,000 molecules for possible efficacy as an antiviral treatment, and then analyzed 7,000 specimens that showed potential through laboratory tests. Raloxifene was found to be the "most promising” of 40 molecules that showed activity against the novel coronavirus, according to a statement from the European Commission. Researchers said it will require full clinical trials to determine whether the drug would effectively treat infected patients, but the data suggest it might be able to stem the spread of the disease in mild and asymptomatic cases. The consortium is in negotiations about clinical trials that could begin this summer.